Bristol Myers licenses immunotherapy from Dragonfly

By The Science Advisory Board staff writers

August 10, 2020 -- Bristol Myers Squibb has paid $12 million to Dragonfly Therapeutics to license a fourth immunotherapy drug candidate from Dragonfly's TrinKet portfolio.

The deal will allow Dragonfly to further develop new natural killer cell-based treatment options for patients with cancer, autoimmune disease, and neurological conditions, it said. This is the fourth licensing agreement between the two firms since 2017.

Dragonfly, Bristol Myers Squibb to develop immunotherapies
Dragonfly Therapeutics has entered into a research collaboration with Bristol Myers Squibb to discover and develop novel immunotherapies for multiple...
AACR launches $36M genomics project with big pharma
The American Association for Cancer Research (AACR) is launching a $36 million research project in collaboration with big pharma to expand its Genomics...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter